VEGFA and hepatocellular carcinoma: The analysis of serum biomarkers in patients enrolled in this trial has detected the potential negative prognostic role of baseline VEGF, ANG2 and FGF21, regardless of the drug used [50], whilst elevation of FGF23 levels, as previously reported in thyroid cancer patients responding to lenvatinib therapy [51], was observed when complete or partial responses were reached in HCC patients treated with lenvatinib.